IFF reports Q1 adjusted EPS $1.13c, consensus 86c

Reports Q1 revenue $2.9B, consensus . On a comparable basis, currency neutral sales increased 5% versus the prior-year period led by growth in Scent, Health & Biosciences and Nourish. Volume grew mid-single digits and continued to improve sequentially across nearly all businesses. The company said, “We have started the year well, with good results across the majority of our business. In the first quarter, we delivered volume growth and productivity gains, which resulted in solid top-and-bottom-line results on a comparable basis. We are off to a good start, yet recognize that it is still early in the year and uncertainty remains. Based on our performance to date and our outlook for the balance of the year, we believe results will likely trend towards the higher-end of our previously announced guidance ranges.”